Calcification in end-stage kidneys

Ibels, L. S.; Alfrey, Allen C.; Huffer, William E.; Craswell, Peter W.; Weil, Richard

doi:10.1016/0002-9343(81)90255-2

Cited by 54 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was about 5-fold higher in kidney disease with preserved kidney func tion than in normal kidneys and much more so in kidney disease with renal failure, namely with a serum creati nine > 1.5 mg%. Ibels et al [20] concurred with these results.…”

Section: Discussionmentioning

confidence: 62%

Effect of the Calcium Channel Blocker Nisoldipine on the Progression of Chronic Renal Failure in Man

et al. 1988

View full text Add to dashboard Cite

Patients with stable renal insufficiency were randomized into two groups: (1) patients given the channel blocker nisoldipine (n = 17) and (2) placebo-treated patients (n = 17) also taking their regular antihypertensive therapy which did not include calcium blockers. Patients were already on low protein diet with a protein intake of 0.80 ± 0.2 in the nisoldipine group versus 0.85 ± 0.25 g/kg body weight in the placebo-treated group. The monthly progression of their renal failure was assessed by the reciprocal of serum creatinine versus time in months. After a mean follow-up of 17.4 ± 8.2 (range 6–30) months, the nisoldipine-treated group had a significant decrease in their slope of progression, whereas the placebo-treated patients, after 16.94 ± 7.2 (range 6–30) months of follow-up, had no significant change in their slope. The protein intake during follow-up was similar, being 0.85 ± 0.2 g/kg actual body weight in the nisoldipine-treated group and 0.88 ± 0.26 g/kg in the placebo group. The changes in slope did not correlate with the changes in blood pressure.

show abstract

Section: Discussionmentioning

confidence: 62%

Effect of the Calcium Channel Blocker Nisoldipine on the Progression of Chronic Renal Failure in Man

et al. 1988

View full text Add to dashboard Cite

show abstract

“…These sonographic features helped to establish the diagnosis of RPN in 7 patients on maintenance dialysis or renal transplantation with a his tory of significant analgesic abuse. Patients on mainte nance dialysis due to diseases other than AN may also show renal calcifications due to imbalances in calcium and phosphorus homeostasis [6]. Sonography done in the negative control group, however, excludes this possibil ity in our study as only 1 of the 12 patients studied demonstrated renal papillary calcification.…”

Section: Discussionmentioning

confidence: 71%

Paracetamol: A Cause for Analgesic Nephropathy and End-Stage Renal Disease

Segasothy

Ab²,

Puvaneswary³

et al. 1988

Nephron

View full text Add to dashboard Cite

180 patients with end-stage renal disease (ESRD) on maintenance dialysis and those who had undergone renal transplantation were questioned retrospectively. 14 patients had consumed excessive quantities of analgesics ( > l kg) prior to the institution of long-term dialysis or transplantation. Sonographic examination done on these patients indicated that 7 had renal papillary necrosis (RPN). The sonographic features were renal papillary calcifications surrounding the central sinus in a complete or incomplete garland pattern. In 5 of these patients RPN is attibutable to the excessive consumption of paracetamol. We have earlier reported 10 cases of RPN due to excessive consumption of paracetamol. Thus 15 cases of RPN attributable to paracetamol consumption (1.0–15.3 kg over a period ranging from 3 to 23 years) have been documented. It is concluded that paracetamol may assume an increasingly important role in the causation of analgesic nephropathy (AN) and ESRD.

show abstract

“…Other diseases with periodic renal calcifica tions including medullary sponge kidneys also must be considered in differential diagnosis. Patients on mainte nance dialysis due to diseases other than analgesic ne phropathy may also show renal calcifications due to imbalances in calcium and phosphorus homeostasis [17]. These calcifications sometimes form a garland arrange ment and analgesic nephropathy should be considered as the underlying disease only in characteristic cases.…”

Section: Discussionmentioning

confidence: 99%

Ultrasonic Findings in Analgesic Nephropathy

Weber

Braun

Köhler

1985

Nephron

View full text Add to dashboard Cite

34 patients with analgesic nephropathy (AN) were investigated by real-time ultrasonography. In 11 out of 14 patients on maintenance dialysis and in 16 out of 20 patients with renal insufficiency calcified renal papillae were documented surrounding the central sinus in a typical garland pattern. Moreover, by surveying a group of patients with renal insufficiency of unknown origin, AN was assumed in 10 patients and was then confirmed by a hitherto unknown history of analgesic abuse as well as by laboratory findings. In 37 patients radiologic or autopsy data were additionally available. A close correlation to the scanning pattern was found in 31 of these patients. In 30 healthy volunteers and 56 patients with renal insufficiency due to chronic glomerulonephritis (n = 24) or diabetic nephropathy (n = 32) calcified renal papillae were found only in 1 case. 5 out of 20 patients on maintenance dialysis due to other diseases than AN showed renal calcifications forming an approximate garland arrangement. In these patients sonography may therefore indicate AN only in very characteristic cases. We believe that renal papillary calcifications surrounding the central sinus in a garland pattern may indicate AN in most cases and thus may be helpful in establishing the diagnosis of AN.

show abstract

Calcification in end-stage kidneys

Cited by 54 publications

References 14 publications

Effect of the Calcium Channel Blocker Nisoldipine on the Progression of Chronic Renal Failure in Man

Effect of the Calcium Channel Blocker Nisoldipine on the Progression of Chronic Renal Failure in Man

Paracetamol: A Cause for Analgesic Nephropathy and End-Stage Renal Disease

Ultrasonic Findings in Analgesic Nephropathy

Contact Info

Product

Resources

About